bupropion / Generic mfg. - LARVOL DELTA

Effort-related motivational effects of the atypical dopamine transport inhibitor vanoxerine in rodent models of decision-making: Interactions with the SSRI fluoxetine and the norepinephrine transport inhibitor atomoxetine. (Neuroscience 2026) - "Drugs that inhibit DAT, such as bupropion, reverse the effects of TBZ, while drugs that selectively inhibit 5-HT or norepinephrine transport (NET) are ineffective...Ongoing studies show that atypical DAT inhibitors such as vanoxerine (GBR 12909), as well as modafinil and several of its analogs, are effective at reversing the effort-related actions of TBZ and enhancing selection of high-effort activities...Similar results were obtained with atomoxetine. These results emphasize the significant role that DA transmission has in regulating exertion of physical effort and effort-based decision making, which has implications for treating effort-related motivational dysfunctions in psychopathology."

Preclinical • CNS Disorders • Depression • Movement Disorders • Parkinson's Disease • Schizophrenia

Evaluation of Antidepressants for Attenuation of Effort-Related Motivational Dysfunction in Male and Female Rats: The Importance of Dopamine Transport Inhibition (Neuroscience 2026) - "Drugs such as serotonin (5-HT) transport (SERT) inhibitors are relatively ineffective at treating motivational impairments and can even exacerbate them, while drugs inhibiting dopamine (DA) and norepinephrine (NE) transporters (DAT and NET) such as bupropion are relatively effective at treating motivational symptoms...Drugs that inhibit DAT produce different dose-related behavioral effects across sexes, and females show larger increases in extracellular DA following administration of some DAT inhibitors, as measured by microdialysis. In summary, facilitation of DA transmission is critical for the attenuation of effort-based motivational dysfunctions, but sex differences must also be taken into account."

Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders

Mouse touchscreen models of effort-based choice for assessing motivational dysfunction: Evaluation of the atypical DAT inhibitor Vanoxerine (Neuroscience 2026) - "Evidence indicates that manipulating dopamine (DA) transmission by antagonizing DA receptors or inhibiting the DA transporter (DAT) - with high selective compounds such as vanoxerine (GBR12909) or less selective, dual reuptake inhibitors like Wellbutrin (bupropion) - can modulate the exertion of effort in humans and rodent models of effort-based decision-making. Results indicate that the DAT inhibitor vanoxerine shifted choice, enhancing the selection of the high effort panel pressing, while the serotonin selective transport inhibitor fluoxetine (Prozac) did not. These findings highlight the role of DA in regulating selection of high-effort activities, and emphasize the potential utility of mouse touchscreen procedures."

Preclinical • CNS Disorders • Depression

Drug repurposing screen of a library of FDA-approved compounds identifies multiple potential PAMs of alpha 7 nAChR: potential utility for nicotine use disorder. (Neuroscience 2026) - "Current FDA-approved tobacco smoking cessation medications [nicotine-replacement therapies (NRTs), varenicline, bupropion] increase the likelihood of long-term quitting ~ 2-3X vs. controls. Compounds A and B (so designated because of proprietary/IP issues) retained their facilitatory effects at a 0.01 uM concentration. We conclude that these compounds are potentially promising α7 PAMs for use in tobacco smoking cessation efforts."

CNS Disorders • Nicotine Addiction • Tobacco Cessation

Comment on "Early Extracorporeal Membrane Oxygenation Support in Bupropion-Induced Cardiogenic Shock". (PubMed, J Emerg Med) - No abstract available

Journal • Cardiovascular

Patient-Level Determinants Outweigh Pharmacotherapy Choice in Smoking Cessation: Evidence from a Real-World Study in Turkey. (PubMed, Healthcare (Basel)) - " In this real-world cohort from Turkey, bupropion plus NRT combination therapy, along with several patient-level factors, was independently associated with 3-month smoking cessation. These findings suggest a potential benefit of combination pharmacotherapy that warrants confirmation in larger, adequately powered studies, and highlight the continued importance of individualized, behaviorally informed cessation strategies, particularly in settings with constrained access to first-line treatments such as varenicline."

Journal • Real-world evidence • Nicotine Addiction • Tobacco Cessation

Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review. (PubMed, J Psychopharmacol) - "Current evidence provides preliminary support that circadian rhythm may differentially affect the pharmacology of select psychotropic agents. Whether the foregoing translates into clinically meaningful differences in efficacy, tolerability, and/or posology of the evaluated agents/classes requires systematic evaluation. Given that evidence is predominantly preclinical, further studies using clinically relevant repeated-dose regimens and disease-relevant animal models are required."

Journal • Review • CNS Disorders • Epilepsy

Smoking Cessation Agent Use and Provider Cessation Advice Among Adults With Gastrointestinal Diseases: Prevalence, Trends, and Predictors (ACG 2026) - "Smoking cessation agents included bupropion, varenicline, and nicotine replacement therapy. The final pooled unweighted sample comprised 2,197 individuals. Over the 12-year study period, 4.7% of our population used smoking cessation agents, with prevalence ranging from 1.4% to 7.3%, and the most recent estimate at 4.8% in 2023. Among cessation agent users, the median age was 54 years, 67% were females, 85% were non-Hispanic White, while majority (68%) used bupropion only."

Clinical • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Tobacco Cessation

Racial and Ethnic Disparities in Mood Disorder Diagnosis and Antidepressant Use Among Women With Inflammatory Bowel Disease (ACG 2026) - "Primary outcomes were new diagnoses of depression and anxiety, and antidepressant initiation (SSRI, SNRI, bupropion)... Crohn's disease prevalence was similar between White and Black women (7.7% vs. 7.5%), while ulcerative colitis was more prevalent in White women (5.7% vs. 4.8%)."

Clinical • CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mental Retardation • Mood Disorders • Psychiatry • Ulcerative Colitis

Atypical Collagenous Colitis Presenting With Diffuse Pancolitis and Macroscopic Ulcerations (ACG 2026) - "Her only medication was bupropion...IV methylprednisolone was started for presumed IBD...However, histologic findings and complete clinical and endoscopic resolution with budesonide, the first-line therapy, favors the diagnosis of CC and makes IBD less likely...1 Colonoscopy showing diffuse inflammation with ulceration Figure: Fig. 2 Collagenous colitis with thickened subepithelial collagen"

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Smoking Cessation Engagement Is Associated With Improved Outcomes in Chronic Pancreatitis (ACG 2026) - "The cessation cohort comprised patients with documented cessation: pharmacotherapy (varenicline, bupropion, or nicotine replacement therapy) and/or smoking/tobacco cessation counseling (CPT codes); the comparator comprised active smokers with no cessation-related prescriptions or ICD-10 codes. After matching, 11,867 patients were included in each cohort; the median age was 55 years, and 67% were male. Cessation attempts were associated with lower 3-year risk of AP (13.2% vs. 15.1%; RR 0.870, 95% CI 0.798-0.949; p = 0.0015) and pancreatic malignancy (2.7% vs."

Diabetes • Metabolic Disorders • Pancreatic Cancer • Pancreatitis • Solid Tumor • Tobacco Cessation

Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD. (PubMed, Kidney Int Rep) - "The Combination of Novel Therapies for CKD Comorbid Depression Trial (CONCORD) is a multicenter, randomized, placebo-controlled trial to evaluate 2 distinct treatment strategies compared with control in participants with CKD G3b-5 and MDD, beginning with 8 weeks of monotherapy with single-blind behavioral activation teletherapy (BAT) plus double-blind placebo, or double-blind bupropion-sustained release once daily plus single-blind attention control clinical management (CM). The percentages with CKD G3b, G4, G5, and G5D were 35.6%, 43.6%, 10.9%, and 9.9%, respectively. CONCORD will provide evidence for the effectiveness of bupropion, BAT, and combination therapy for depression in adults with CKD, which can inform changes in clinical practice."

Journal • Chronic Kidney Disease • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Nephrology • Psychiatry • Renal Disease

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial (clinicaltrials.gov) - P4 | N=794 | Not yet recruiting | Sponsor: Yale University

New P4 trial • Human Immunodeficiency Virus • Infectious Disease • Nicotine Addiction • Tobacco Addiction • Tobacco Cessation

INAVO121: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (clinicaltrials.gov) - P3 | N=420 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2 • PIK3CA

Auvelity (Dextromethorphan-Bupropion) for Agitation and Aggression in Alzheimer's Disease Dementia: Mechanism, Efficacy, Safety, and Clinical Considerations. (PubMed, Psychopharmacol Bull) - "Clinicians must, however, monitor for blood pressure changes and potential CYP2D6 drug-drug interactions. Dextromethorphan-bupropion represents a highly efficacious, safer paradigm shift in the pharmacological management of AD-associated agitation, offering targeted symptom relief while minimizing the severe risks associated with standard antipsychotic use."

Journal • Review • Alzheimer's Disease • Anesthesia • CNS Disorders • Cognitive Disorders • Dementia

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Epygenix

New P1 trial

Progress in the use of smoking cessation medications for vaping cessation: a review (ERS 2026) - "Aims: To synthesize contemporary research on the efficacy and safety of nicotine replacement therapy (NRT), varenicline, and bupropion for vaping cessation. Smoking cessation medications, particularly varenicline, offer significant potential for treating e-cigarette dependence. Future research must prioritize large-scale, vaping-specific randomized controlled trials to establish definitive clinical protocols."

Review • Insomnia • Nicotine Addiction • Sleep Disorder • Tobacco Addiction • Tobacco Cessation

Real-World Evidence of Cytisine Use in Türkiye: Quit Rates and Determinants of Smoking Cessation (ERS 2026) - "Between January 2024 and October 2025, 494 smokers attending a smoking cessation clinic in Türkiye received cytisine, bupropion, or nicotine replacement therapy (NRT), combined with behavioral counseling...Cytisine combined with behavioral counseling was associated with higher abstinence rates and good tolerability. These findings support its integration into smoking cessation services in Türkiye."

Clinical • HEOR • Real-world • Real-world evidence • Nicotine Addiction • Tobacco Cessation

FULMINANT BUPROPION CARDIOTOXICITY RESULTING IN REVERSIBLE CARDIOGENIC SHOCK AND DELAYED NEUROLOGIC RECOVERY SUPPORTED BY VA-ECMO (CHEST 2026) - No abstract available

Cardiovascular

Emergency Department Management of Nicotine Use: A White Paper Prepared for the American Academy of Emergency Medicine. (PubMed, J Emerg Med) - "Emergency physicians have an important opportunity to meaningfully reduce morbidity and mortality for patients with NUD by starting safe and evidence-based NUD treatments. We recommend that all patients with NUD presenting to the acute care setting be offered medications for NUD as well as brief counseling on NUD, and be referred to local outpatient follow up or other available resources for continued NUD care on discharge."

Journal • CNS Disorders • Nicotine Addiction • Psychiatry • Tobacco Cessation

Long-Term Rural-Urban Trends in Tobacco Use, Cessation Interventions, and Lung Cancer Screening - 10-Year Retrospective Cohort Study (IASLC-WCLC 2026) - "Cessation interventions included documented counseling, nicotine replacement therapy, and bupropion and/or varenicline prescriptions. These patterns underscore the need for effective efforts to mitigate barriers to smoking cessation and lung cancer screening across all populations, particularly rural areas. There is also need for data systems to address limitations inherent in clinical data."

Retrospective data • Lung Cancer • Oncology • Solid Tumor • Tobacco Cessation

The influence of pharmacogenetics on the treatment-related outcomes of antidepressants and antipsychotics in Brazil: a systematic review. (PubMed, Pharmacogenomics) - "In schizophrenia, variants in CYP2C19, DRD1, DRD2, and CYP1A2 were associated with clozapine safety and response...For smoking cessation, CYP2B6 rs2279343 AA showed greater success with bupropion...Therefore, routine pharmacogenetic testing in Brazilian psychiatric practice remains premature. PROSPERO CRD42024533782."

Biomarker • Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Schizophrenia • Tobacco Cessation • CYP1A2 • CYP2C19 • DRD2 • HTR2A

Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies. (PubMed, Medicina (Kaunas)) - "Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily indirectly through weight reduction and metabolic improvement...However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required."

Clinical • Journal • Review • Diabetes • Genetic Disorders • Gestational Diabetes • Gynecology • Infertility • Inflammation • Metabolic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders • Women's Health • LEP

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression. (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Washington University School of Medicine

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry